TITLE

New Challenges for NICE

AUTHOR(S)
Upton, Julian
PUB. DATE
February 2010
SOURCE
Pharmaceutical Executive;Feb2010, Vol. 30 Issue 2, p26
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article presents the challenges faced by the National Institute for Health and Clinical Excellence (NICE) to address application of cost-effective health resource allocation in Great Britain. It mentions the criticism faced by NICE concerning the quality-adjusted life year (QALY) as metric for determining broader merits of innovative drug treatments. It also notes the questions raised concerning the 2.5 million pounds budget for the Life Sciences Blueprint scheme of NICE.
ACCESSION #
48274508

 

Related Articles

  • Rationing: it would be NICE to consider patients' views. Speight, Jane; Reaney, Matt // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;1/31/2009, p297 

    The article offers the author's personal view on rationing health care and the cost effectiveness criteria set out by the National Institute for Health and Clinical Excellence (NICE) in Great Britain. Topics include NICE's appraisals of quality adjusted life years or QALYs by a method called...

  • Should NICE'S threshold range for cost per QALY be raised? Towse, Adrian // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;1/31/2009, p268 

    The article argues that the National Institute for Health and Clinical Excellence should fund cost-effective treatments. Topics are the guidelines for quality adjusted life year (QALY), the willingness of taxpayers to support the treatment costs for end-of-life drugs, the opportunity costs that...

  • NICE recommendations submitted by Kennedy.  // PharmacoEconomics & Outcomes News;8/8/2009, Issue 584, p3 

    The article focuses on the recommendations submitted by Professor Sir Ian Kennedy to the British National Institute for Health and Clinical Excellence (NICE) for the inclusion of social benefits in the institute's appraisals structure. Kennedy believes that such benefits should not create an...

  • NICE and the challenge of cancer drugs. Raftery, James // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;1/31/2009, p271 

    The article discusses the criteria introduced by the National Institute for Health and Clinical Excellence (NICE) in Great Britain and the guidelines for end of life treatment. There is a controversy over the cost effectiveness of cancer-therapy drugs because trastuzumab and imatinib, which the...

  • A Review and Critique of Studies Reporting Utility Values for Schizophrenia-Related Health States. Mavranezouli, Ifigeneia // PharmacoEconomics;2010, Vol. 28 Issue 12, p1109 

    Economic evaluation of health technologies in the form of cost-utility analysis is increasingly advocated. The most common outcome measure in this type of analysis is the QALY. In order to estimate QALYs, appropriate utility values are required. The objective of this review was to identify and...

  • NICE says Inditherm blanket cost effective. McCarty, Mark // Medical Device Daily;9/1/2011, Vol. 15 Issue 167, p8 

    The article reports that the National Institutes of Health and Clinical Excellence (NICE) in Great Britain found the patient warming mattress of Inditherm to be cost effective.

  • Mapping for economic evaluation. Chuang, Ling-Hsiang; Whitehead, Sarah J. // British Medical Bulletin;Mar2012, Vol. 101 Issue 1, p1 

    Introduction/background Mapping provides a statistical algorithm that allows the estimation of utilities and consequently calculation of QALYs in clinical studies where preference-based measures are not implemented. Sources of data Reviews of the mapping literature were utilized. Areas of...

  • Eltrombopag for the Treatment of Chronic Immune or Idiopathic Thrombocytopenic Purpura: A NICE Single Technology Appraisal. Boyers, Dwayne; Xueli Jia; Jenkinson, David; Mowatt, Graham // PharmacoEconomics;2012, Vol. 30 Issue 6, p483 

    The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of eltrombopag (GlaxoSmithKline) to submit evidence for the clinical and cost effectiveness of this drug for the treatment of patients with chronic immune or idiopathic thrombocytopenic purpura (ITP), as...

  • NICE to extend end-of-life drug funding.  // PharmacoEconomics & Outcomes News;4/1/2013, Issue 675, p9 

    The article reports on the implications of the decision made by the National Institute for Health and Care Excellence (NICE) to improve the Great Britain National Health Service (NHS), which may lead to significant quality-adjusted life year (QALY) losses and budgetary problems to the service.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics